Peetz Christopher
Peetz Christopher, CEO, reported a transaction classified as exercise at Mirum Pharmaceuticals, Inc. involving 30000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 58487.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Sep 01, 2026
- Filing date
- Sep 03, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
MIRM price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001614740-26-000013 Employee Stock Option (right to buy)
- Transaction date
- Sep 01, 2026 Filed Sep 03, 2026, 10:52 PM · 2d delay
- Shares
- 30,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 58,487 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-16 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CHIEF EXECUTIVE OFFICER
- F1
Includes 131 shares of Common Stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.
- F2
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
- F3
The weighted average sale price for the transaction reported was $98.08, and the range of prices were between $97.47 and $98.42. Upon request by the SEC staff, the Issuer, or any security holder of th…
- F4
The weighted average sale price for the transaction reported was $98.91, and the range of prices were between $98.49 and $99.38. Upon request by the SEC staff, the Issuer, or any security holder of th…
- F5
The stock option is fully vested.
0 other transactions
0 recent txs